METiS Technologies Secures Series D Funding for AI-Driven Nanodelivery

METiS Technologies has successfully closed a RMB 400 million Series D financing round, announced in a press release. The funding was co-led by the Beijing Medical and Health Industry Investment Fund and the Daxing Industrial Investment Fund. This capital injection will be used to accelerate METiS' strategic initiatives, including automation upgrades to its proprietary platform, in-house pipeline development, and expansion of global partnerships.

The financing round was announced at the Zhongguancun (Daxing) Cell and Gene Therapy Industrial Park, a significant hub for Beijing's life sciences sector. The funds will also support the recruitment of world-class talent, further enhancing METiS' capabilities in AI-driven nanodelivery innovation.

METiS Technologies is at the forefront of AI and nanomaterial science, focusing on transforming the delivery and application of active agents across various life forms. The company's proprietary platforms, such as AiLNP, AiRNA, and AiTEM, simulate and predict nanoscale interactions to optimize the design and validation of next-generation nanomaterials.